Bcl-2/bax mRNA expression ratio as prognostic factor in low-grade urinary bladder cancer

International Journal of Cancer. Journal International Du Cancer
P GazzanigaA M Agliano

Abstract

Apoptotic cell death represents an important mechanism for the precise regulation of cell numbers, and a defence mechanism against tumoral cell. bcl-2 and bax genes are known to be involved in the control of apoptotic pathways; in particular, the ratio between bcl-2 and bax represents a cell rheostat that is able to predict a cell's response toward life or death to an apoptotic stimulus. In the present study we investigated the role of bcl-2 and bax gene expression in a panel of 37 low-grade tumours of the urinary bladder, and correlated the expression of these genes to the prognosis of patients in a follow-up of more than one year. We found that levels of bax expression higher than bcl-2 in bladder tumours well correlates to a better outcome for patients. Early relapses are much more frequently observed in those patients whose tumours express more bcl-2 than bax mRNA. We conclude that the bcl-2/bax expression ratio may be considered as a marker for disease progression in low grade bladder tumours, independently of clinical staging and histological grading.

References

Jan 1, 1991·International Review of Experimental Pathology·M J Arends, A H Wyllie
Feb 1, 1990·British Journal of Urology·P J RussellD Raghavan
Jan 6, 1993·Journal of the National Cancer Institute·A S SarkisV E Reuter
Apr 20, 1995·Nature·T ChittendenB C Guild
Jan 2, 1993·International Journal of Cancer. Journal International Du Cancer·Q L LuJ A Thomas
Nov 1, 1995·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·P GazzanigaA M Agliano

❮ Previous
Next ❯

Citations

Jun 19, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Ramji R Rajendran, Gary D Kao
Aug 9, 2011·Vojnosanitetski pregled. Military-medical and pharmaceutical review·Ana RistićDragana Stokanović
Sep 24, 2009·Expert Opinion on Emerging Drugs·Chris Protzel, Oliver W Hakenberg
Apr 17, 2012·Neurotoxicology and Teratology·Ya-xing GuiSheng-di Chen
Apr 15, 2005·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Monica FalleniSilvano Bosari
Feb 15, 2001·The Journal of Urology·B J DugganUNKNOWN Belfast Uro-oncology Research Group
Nov 24, 2012·Expert Opinion on Therapeutic Targets·Shibu ThomasPaul B Fisher
Apr 2, 2015·Biochimica Et Biophysica Acta·Cristina CorreiaScott H Kaufmann
Dec 21, 2000·Japanese Journal of Cancer Research : Gann·A Salah-eldinA Matsuura
Aug 5, 2000·International Journal of Cancer. Journal International Du Cancer·I SturmP T Daniel
May 16, 1998·International Journal of Cancer. Journal International Du Cancer·A SierraA Fabra
Jan 15, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Angela GradiloneAnna Maria Aglianò
Mar 27, 2003·The Annals of Otology, Rhinology, and Laryngology·Anastasia GeorgiouEleutherios Ferekidis
Aug 8, 2006·Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc·Wu YinQiao Zhou
Feb 16, 2005·The Journal of Urology·John Joseph McKnightKate E Williamson
May 1, 2008·Pflügers Archiv : European journal of physiology·Anja Meissner, Thomas Noack
Feb 23, 2020·Journal of Toxicology and Environmental Health. Part a·Katriane Neto da SilvaViviane Glaser
Dec 13, 1996·The Journal of Biological Chemistry·J R SingletonE L Feldman
Sep 1, 1997·The Prostate·D G Tang, A T Porter
Apr 18, 2013·Biological Trace Element Research·Shu-ying YangZi-gui Zhang
Aug 5, 1998·The American Journal of Physiology·S R NarasimhanV C Broaddus
Jan 16, 2015·The International Journal of Biological Markers·Federico Maria GioacchiniMassimo Re
Mar 9, 2017·Evidence-based Complementary and Alternative Medicine : ECAM·Shu RuanJianbo Li
Dec 1, 2020·European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences·Hesham HaffezZeinab A Hassan
Jan 23, 2021·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Mohamed R AbdelaalHesham Haffez
Nov 3, 1998·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·P GazzanigaA M Agliano

❮ Previous
Next ❯

Related Concepts

Related Feeds

Bladder Carcinoma In Situ

Bladder Carcinoma In Situ is a superficial bladder cancer that occurs on the surface layer of the bladder. Discover the latest research on this precancerous condition in this feed.

BCL-2 Family Proteins

BLC-2 family proteins are a group that share the same homologous BH domain. They play many different roles including pro-survival signals, mitochondria-mediated apoptosis and removal or damaged cells. They are often regulated by phosphorylation, affecting their catalytic activity. Here is the latest research on BCL-2 family proteins.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis